{"id":11730,"date":"2020-06-25T14:19:03","date_gmt":"2020-06-25T08:49:03","guid":{"rendered":"https:\/\/www.rootsanalysis.com\/blog\/?p=11730"},"modified":"2026-07-27T13:33:09","modified_gmt":"2026-07-27T08:03:09","slug":"drug-targeting-synthetically-lethal-targets","status":"publish","type":"post","link":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/","title":{"rendered":"PARP Inhibitors for Treatment of Advanced Cancer Indications"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. <a href=\"https:\/\/www.iarc.fr\/\">The International Agency for Research on Cancer<\/a> (IARC) states that the number of new cancer cases is expected to grow to 27.5 million across the globe, by 2040. Experimental evidence has shown that defects in the <a href=\"https:\/\/www.rootsanalysis.com\/reports\/parp-inhibitors-market\/267.html\">DNA repair<\/a> machinery are one of the primary causes for both generation and maintenance of cancer. It is a well-known fact that DNA is the reservoir of genetic information in all cells. Defects in deoxyribonucleic acid (DNA) repair have been shown to be one of the primary causes of cancer. Moreover, tumor cells that are characterized by impaired DNA repair pathways typically become reliant on alternative DNA repair pathways for survival. This phenomenon is commonly referred to as oncogene addiction.&nbsp;Currently, there are four approved (and marketed) poly-ADP ribose polymerase <a href=\"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/\">(PARP) inhibitors<\/a>, which have been shown to operate based on the concept of synthetic lethality to target these cancerous cells.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"615\" height=\"173\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Benefits-of-Synthetic-Lethality-Based-Drugs-Roots.webp\" alt=\"synthetic lethality\" class=\"wp-image-19562\" style=\"object-fit:contain;width:800px;height:228px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Benefits-of-Synthetic-Lethality-Based-Drugs-Roots.webp 615w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Benefits-of-Synthetic-Lethality-Based-Drugs-Roots-300x84.webp 300w\" sizes=\"auto, (max-width: 615px) 100vw, 615px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What is the Basic Concept of Synthetic Lethality and PARP Inhibitors?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">PARP Inhibitors of compensatory repair pathways have the potential to sensitize cancer cells to DNA damaging agents and other therapeutic regimens. On the other hand, the simultaneous inactivation of certain pairs of genes have been shown to cause cell death. This phenomenon is known as synthetic lethality. In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"564\" height=\"359\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Basic-Concept-of-Synthetic-Lethality-RootsAnalysis.webp\" alt=\"Synthetic Lethality and PARP Inhibitors\" class=\"wp-image-19563\" style=\"object-fit:contain;width:556px;height:362px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Basic-Concept-of-Synthetic-Lethality-RootsAnalysis.webp 564w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Basic-Concept-of-Synthetic-Lethality-RootsAnalysis-300x191.webp 300w\" sizes=\"auto, (max-width: 564px) 100vw, 564px\" \/><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\"><strong>What is the recent activity on Social Media Platforms?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Further, recent activity on Twitter (2,100+ tweets) confirms the rising interest in this domain as stakeholders attempt to harness the therapeutic potential of synthetic lethality. In addition to <a href=\"https:\/\/www.rootsanalysis.com\/key-insights\/merck-collaboration-with-hengrui.html\">PARP1 inhibitors<\/a> \/ BRCA mutations, ATM, ATR, CHK1, KRAS and RAD51, are presently considered amongst the most prominent synlet targets, which are being investigated in the clinical stages of development. Further, CDK12, PI3K, PLK1, PTEN, SNF and WRN are synlet targets that are currently being evaluated in preclinical studies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"615\" height=\"346\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Social-Media-Analysis-Roots-1.webp\" alt=\"PARP Inhibitors Social Media Analysis\" class=\"wp-image-19564\" style=\"object-fit:contain;width:800px;height:457px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Social-Media-Analysis-Roots-1.webp 615w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Social-Media-Analysis-Roots-1-300x169.webp 300w\" sizes=\"auto, (max-width: 615px) 100vw, 615px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What are the most popular synlet targets being explored for PARP inhibitors drug development?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Significant advances in research have led to the discovery of a wide array of synlet targets; over time, substantial intellectual capital has been generated and validated by eminent scientists from renowned research institutes. Specifically, 55+ targets are already clinically \/ preclinically validated, while over 160 targets have been mentioned in various research publications (with no drug candidate so far).<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"615\" height=\"345\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Benchmark-Analysis-Roots.webp\" alt=\"synthetic lethality Based Drugs\" class=\"wp-image-19565\" style=\"object-fit:contain;width:800px;height:453px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Benchmark-Analysis-Roots.webp 615w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Benchmark-Analysis-Roots-300x168.webp 300w\" sizes=\"auto, (max-width: 615px) 100vw, 615px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Recent Approvals: Drug Watch 2020<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">It is worth noting that, till date, only four molecules have been marketed, namely olaparib (2014), rucaparib (2016), niraparib (2017) and talazoparib (2018). Recently, in April 2020, the USFDA approved GSK&#8217;s PARP inhibitors, niraparib, for expanded use as a maintenance therapy in advanced ovarian, fallopian tube, or primary peritoneal cancer patients in complete or partial response to frontline platinum-based chemotherapy. In January 2020, the USFDA granted priority review designation to a supplemental new drug application (sNDA) for olaparib as maintenance therapy in advanced ovarian, fallopian tube, or primary peritoneal cancer patients in complete or partial response to frontline platinum-based chemotherapy. In January 2020, NICE recommended olaparib for use in the NHS for BRCA-positive patients in the second-line, post-platinum-chemotherapy treatment setting for ovarian cancer. In January 2020, the USFDA granted fast track designation to Clovis Oncology\u2019s rucaparib for prostate cancer. In addition, two molecules, veliparib (developed by AbbVie) and pamiparib (developed by BeiGene), are in phase III of development and are likely to reach the market in the near future.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How is the current and estimated opportunity segmented across key market segments?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The present <a href=\"https:\/\/www.rootsanalysis.com\/reports\/parp-inhibitors-market\/267.html\">PARP inhibitors market<\/a> is driven by the sales generated by four approved PARP inhibitors, niraparib, olaparib, rucaparib and talazoparib. Future growth of the market is likely to be driven by the success of clinical outcomes of late-stage molecules; industry stakeholders are optimistic about the vast potential of PARP inhibitors.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"615\" height=\"339\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Market-Segmentation-Roots.webp\" alt=\" PARP Inhibitors Regional Analysis\" class=\"wp-image-19567\" style=\"object-fit:contain;width:800px;height:458px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Market-Segmentation-Roots.webp 615w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/Synthetic-Lethality-Market-Segmentation-Roots-300x165.webp 300w\" sizes=\"auto, (max-width: 615px) 100vw, 615px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">To get detailed insights on the key players, synlet targets, funding and investment trends research landscape, recent developments and the likely market evolution, you can also download the&nbsp;<a href=\"https:\/\/www.rootsanalysis.com\/reports\/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-\/request-sample.html\">SAMPLE REPORT<\/a>&nbsp;on PARP inhibitors by Roots Analysis<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5 million across the globe, by 2040. Experimental evidence has shown [&hellip;]<\/p>\n","protected":false},"author":21,"featured_media":11736,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[311,430],"tags":[53,263,188],"class_list":["post-11730","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-therapeutics","tag-cancer","tag-cancer-therapies","tag-drug-discovery"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Treatment of Advanced Cancer Indications by PARP Inhibitors<\/title>\n<meta name=\"description\" content=\"According to Roots Analysis, the present market is driven by four approved PARP inhibitors, niraparib, olaparib, rucaparib and talazoparib.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Treatment of Advanced Cancer Indications by PARP Inhibitors\" \/>\n<meta property=\"og:description\" content=\"According to Roots Analysis, the present market is driven by four approved PARP inhibitors, niraparib, olaparib, rucaparib and talazoparib.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RootsAnalysis\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-25T08:49:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-27T08:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2020\/06\/pexels-photo-4047186.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"867\" \/>\n\t<meta property=\"og:image:height\" content=\"1300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Gaurav Chaudhary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:site\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gaurav Chaudhary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/\"},\"author\":{\"name\":\"Gaurav Chaudhary\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/e8e0ebc31296140424e1e7fcc11331bc\"},\"headline\":\"PARP Inhibitors for Treatment of Advanced Cancer Indications\",\"datePublished\":\"2020-06-25T08:49:03+00:00\",\"dateModified\":\"2026-07-27T08:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/\"},\"wordCount\":696,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/pexels-photo-4047186.jpeg\",\"keywords\":[\"Cancer\",\"Cancer Therapies\",\"Drug Discovery\"],\"articleSection\":[\"Cancer\",\"cancer therapeutics\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/\",\"name\":\"Treatment of Advanced Cancer Indications by PARP Inhibitors\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/pexels-photo-4047186.jpeg\",\"datePublished\":\"2020-06-25T08:49:03+00:00\",\"dateModified\":\"2026-07-27T08:03:09+00:00\",\"description\":\"According to Roots Analysis, the present market is driven by four approved PARP inhibitors, niraparib, olaparib, rucaparib and talazoparib.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/pexels-photo-4047186.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/pexels-photo-4047186.jpeg\",\"width\":867,\"height\":1300,\"caption\":\"Rootsanalysis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/drug-targeting-synthetically-lethal-targets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PARP Inhibitors for Treatment of Advanced Cancer Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"name\":\"Blog\",\"description\":\"Roots Analysis\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\",\"name\":\"Roots Analysis\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"width\":205,\"height\":61,\"caption\":\"Roots Analysis\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RootsAnalysis\\\/\",\"https:\\\/\\\/x.com\\\/RootsAnalysis\",\"https:\\\/\\\/www.instagram.com\\\/rootsanalysis\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/roots-analysis\\\/\",\"https:\\\/\\\/www.pinterest.it\\\/analysis1340\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCwZF57vY1lnU0bNLej2zukg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/e8e0ebc31296140424e1e7fcc11331bc\",\"name\":\"Gaurav Chaudhary\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"caption\":\"Gaurav Chaudhary\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Treatment of Advanced Cancer Indications by PARP Inhibitors","description":"According to Roots Analysis, the present market is driven by four approved PARP inhibitors, niraparib, olaparib, rucaparib and talazoparib.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/","og_locale":"en_US","og_type":"article","og_title":"Treatment of Advanced Cancer Indications by PARP Inhibitors","og_description":"According to Roots Analysis, the present market is driven by four approved PARP inhibitors, niraparib, olaparib, rucaparib and talazoparib.","og_url":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/","og_site_name":"Blog","article_publisher":"https:\/\/www.facebook.com\/RootsAnalysis\/","article_published_time":"2020-06-25T08:49:03+00:00","article_modified_time":"2026-07-27T08:03:09+00:00","og_image":[{"width":867,"height":1300,"url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2020\/06\/pexels-photo-4047186.jpeg","type":"image\/jpeg"}],"author":"Gaurav Chaudhary","twitter_card":"summary_large_image","twitter_creator":"@RootsAnalysis","twitter_site":"@RootsAnalysis","twitter_misc":{"Written by":"Gaurav Chaudhary","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/#article","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/"},"author":{"name":"Gaurav Chaudhary","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/e8e0ebc31296140424e1e7fcc11331bc"},"headline":"PARP Inhibitors for Treatment of Advanced Cancer Indications","datePublished":"2020-06-25T08:49:03+00:00","dateModified":"2026-07-27T08:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/"},"wordCount":696,"publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2020\/06\/pexels-photo-4047186.jpeg","keywords":["Cancer","Cancer Therapies","Drug Discovery"],"articleSection":["Cancer","cancer therapeutics"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/","url":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/","name":"Treatment of Advanced Cancer Indications by PARP Inhibitors","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/#primaryimage"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2020\/06\/pexels-photo-4047186.jpeg","datePublished":"2020-06-25T08:49:03+00:00","dateModified":"2026-07-27T08:03:09+00:00","description":"According to Roots Analysis, the present market is driven by four approved PARP inhibitors, niraparib, olaparib, rucaparib and talazoparib.","breadcrumb":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/#primaryimage","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2020\/06\/pexels-photo-4047186.jpeg","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2020\/06\/pexels-photo-4047186.jpeg","width":867,"height":1300,"caption":"Rootsanalysis"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rootsanalysis.com\/blog\/drug-targeting-synthetically-lethal-targets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rootsanalysis.com\/blog\/"},{"@type":"ListItem","position":2,"name":"PARP Inhibitors for Treatment of Advanced Cancer Indications"}]},{"@type":"WebSite","@id":"https:\/\/www.rootsanalysis.com\/blog\/#website","url":"https:\/\/www.rootsanalysis.com\/blog\/","name":"Blog","description":"Roots Analysis","publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rootsanalysis.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization","name":"Roots Analysis","url":"https:\/\/www.rootsanalysis.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","width":205,"height":61,"caption":"Roots Analysis"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RootsAnalysis\/","https:\/\/x.com\/RootsAnalysis","https:\/\/www.instagram.com\/rootsanalysis\/","https:\/\/www.linkedin.com\/company\/roots-analysis\/","https:\/\/www.pinterest.it\/analysis1340\/","https:\/\/www.youtube.com\/channel\/UCwZF57vY1lnU0bNLej2zukg"]},{"@type":"Person","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/e8e0ebc31296140424e1e7fcc11331bc","name":"Gaurav Chaudhary","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","caption":"Gaurav Chaudhary"}}]}},"_links":{"self":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/11730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/comments?post=11730"}],"version-history":[{"count":8,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/11730\/revisions"}],"predecessor-version":[{"id":22576,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/11730\/revisions\/22576"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media\/11736"}],"wp:attachment":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media?parent=11730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/categories?post=11730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/tags?post=11730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}